CJC-1295
A long-acting GHRH analog used to elevate endogenous growth hormone and IGF-1.
Research-only·Regulatory status as of May 2026
Relevance for women
A GHRH analog often paired with ipamorelin. Limited human data, and nonclinical findings have flagged safety concerns. Remains restricted under FDA compounding rules as of May 2026 — separate from the peptides removed from Category 2.
Providers that offer CJC-1295
See the full provider comparison for all peptides side by side.